Craig-Hallum Starts Forma Therapeutics (FMTX) at Buy
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Craig-Hallum analyst Robin Garner initiates coverage on Forma Therapeutics (NASDAQ: FMTX) with a Buy rating and a price target of $58.00.
Shares of Forma Therapeutics closed at $22.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Daiwa Starts Walt Disney (DIS) at Buy, Sees Disney+ as Global Streaming Market Leader
- UPDATE: JMP Securities Starts Atlanticus Holdings Corp. (ATLC) at Market Outperform
- Brookline Capital Markets Starts Dermata Therapeutics In (DRMA) at Buy
Create E-mail Alert Related CategoriesHot New Coverage, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!